KUROS BIOSCIENCES AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.48 CHF | +1.25% |
|
-20.20% | +85.67% |
| Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
| Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 34.58 | 55.01 | 66.24 | 63.13 | 53.72 | 128.3 |
| Enterprise Value (EV) 1 | 16.25 | 36.64 | 40.27 | 36.72 | 31.63 | 116.3 |
| P/E ratio | -1.72 x | -3.45 x | -4.26 x | -8.37 x | -3.41 x | -9.18 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 48.4 x | 21.5 x | 16.4 x | 4.57 x | 2.99 x | 3.82 x |
| EV / Revenue | 22.7 x | 14.3 x | 9.97 x | 2.66 x | 1.76 x | 3.46 x |
| EV / EBITDA | -1.38 x | -4.08 x | -4.25 x | -5.79 x | -2.85 x | -17.7 x |
| EV / FCF | -2.08 x | -5.99 x | -5.29 x | 7.01 x | -4.65 x | -16 x |
| FCF Yield | -48.1% | -16.7% | -18.9% | 14.3% | -21.5% | -6.27% |
| Price to Book | 0.45 x | 0.71 x | 0.78 x | 0.82 x | 0.78 x | 2.26 x |
| Nbr of stocks (in thousands) | 15,035 | 22,453 | 32,794 | 32,794 | 36,544 | 36,759 |
| Reference price 2 | 2.300 | 2.450 | 2.020 | 1.925 | 1.470 | 3.490 |
| Announcement Date | 4/12/19 | 3/27/20 | 3/19/21 | 4/5/22 | 3/15/23 | 3/12/24 |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.715 | 2.561 | 4.039 | 13.82 | 17.99 | 33.56 |
| EBITDA 1 | -11.78 | -8.972 | -9.484 | -6.341 | -11.1 | -6.561 |
| EBIT 1 | -13.73 | -11.39 | -11.79 | -8.767 | -13.45 | -8.657 |
| Operating Margin | -1,919.86% | -444.83% | -291.83% | -63.46% | -74.76% | -25.79% |
| Earnings before Tax (EBT) 1 | -13.81 | -11.82 | -12.09 | -9.554 | -15.99 | -13.35 |
| Net income 1 | -11.69 | -11.25 | -11.52 | -7.541 | -14.6 | -13.73 |
| Net margin | -1,635.38% | -439.36% | -285.22% | -54.59% | -81.15% | -40.9% |
| EPS 2 | -1.340 | -0.7111 | -0.4737 | -0.2300 | -0.4305 | -0.3800 |
| Free Cash Flow 1 | -7.812 | -6.116 | -7.605 | 5.237 | -6.797 | -7.29 |
| FCF margin | -1,092.6% | -238.81% | -188.29% | 37.91% | -37.79% | -21.72% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/12/19 | 3/27/20 | 3/19/21 | 4/5/22 | 3/15/23 | 3/12/24 |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 18.3 | 18.4 | 26 | 26.4 | 22.1 | 12 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -7.81 | -6.12 | -7.6 | 5.24 | -6.8 | -7.29 |
| ROE (net income / shareholders' equity) | -15.6% | -14.6% | -14.2% | -9.33% | -20% | -21.9% |
| ROA (Net income/ Total Assets) | -9.98% | -8.2% | -8.09% | -5.9% | -9.64% | -7.01% |
| Assets 1 | 117.1 | 137.2 | 142.5 | 127.8 | 151.3 | 195.9 |
| Book Value Per Share 2 | 5.080 | 3.470 | 2.580 | 2.350 | 1.880 | 1.540 |
| Cash Flow per Share 2 | 1.220 | 0.9300 | 0.8700 | 0.8700 | 0.6600 | 0.3900 |
| Capex 1 | 0.06 | 0.09 | 0.06 | 0.3 | 0.39 | 0.32 |
| Capex / Sales | 8.95% | 3.32% | 1.51% | 2.2% | 2.19% | 0.94% |
| Announcement Date | 4/12/19 | 3/27/20 | 3/19/21 | 4/5/22 | 3/15/23 | 3/12/24 |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +85.67% | 260M | |
| -3.46% | 102B | |
| +1.41% | 96.09B | |
| +2.13% | 22.28B | |
| -15.84% | 21.4B | |
| -9.28% | 18.14B | |
| -39.98% | 17.02B | |
| -14.65% | 16.09B | |
| +4.39% | 13.83B | |
| +31.35% | 11.97B |
- Stock Market
- Equities
- KURN Stock
- Financials Kuros Biosciences AG
